Treatment News : Lower Dose of Kaletra Works Well for Kids With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 18, 2013

Lower Dose of Kaletra Works Well for Kids With HIV

Cutting the standard dose of Kaletra (lopinavir/ritonavir) by 30 percent does not change the antiretroviral’s efficacy at suppressing HIV and it improves rates of abnormal lipid levels among children, aidsmap reports. Investigators conducted a randomized open-label trial at 11 sites in Thailand that included 200 HIV-positive children younger than 18 who weighed between 25 and 50 kilograms (55 to 100 pounds) and who had an undetectable viral load at the outset. They presented their findings at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

The children were randomly assigned to receive the U.S. Food and Drug Administration (FDA)–recommended dose of Kaletra, adjusted for the child’s weight, or 70 percent of that dose. The children took a variety of different nucleoside reverse transcriptase inhibitor backbone regimens.

In the intention-to-treat analysis of the standard dose arm—meaning the analysis was based on the study’s treatment assignment and not on any deviations from that protocol that may have occurred among the participants—91.8 percent of the children had an undetectable viral load after 28 weeks, compared with 88.1 percent of the low dose arm. Meanwhile, in a per protocol analysis, which only considered those who completed the study according to the researchers’ intentions, the proportion who reached an undetectable viral load were a respective 93.7 and 91.8 percent in the standard- vs. the reduced-dose arm.

At the 48-week mark, 34.4 percent of those in the standard-dose arm had cholesterol above 200 milligrams per deciliter compared with 20.6 percent in the low-dose arm. Meanwhile, the respective proportions with triglycerides above 150 mg/dl were 60.4 and 44.3 percent.

To read the conference abstract, click here.

To read the aidsmap story, click here.

Search: Kaletra, HIV, lopinavir, ritonavir, aidsmap, pediatric, children, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013, lipids, cholesterol, triglycerides.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    koffeeboss
    Tucson
    Arizona


    jimmy807
    San Antonio
    Texas


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.